Success Stories: EB-1A Petition Approved in 8 Days for Chinese Postdoctoral Fellow in the Field of Pharmaceutical Sciences (PP Requested, No RFE Issued)
Client’s Testimonial:
“Thanks.”
On September 14th 2016, we received another EB-1A (Alien of Extraordinary Ability) approval for a Scientist in the field of Pharmaceutical Sciences (Approval Notice).
General Field: Pharmaceutical Sciences
Position at the Time of Case Filling: Postdoctoral Research Fellow
Country of Origin: China
Service Center: Texas Service Center (TSC)
State of Residence at the Time of Filling: Oklahoma
Approval Notice Date: September 14th, 2017
Processing Time: 8 days (Premium Processing Requested)
Case summary:
With a Ph.D. in Pharmaceutical Sciences and numerous accolades earned from her research in the same field, our client (a postdoctoral research fellow from China) was a suitable candidate for EB-1A (Alien of Extraordinary Ability). Our main goal was to prove to the USCIS that her research efforts on using computer-aided molecular models to explore and characterize non-calcemic vitamin D derivatives and development of anti-cancer compounds have resulted in important gains to the United States. Additionally, we proved that our client’s research significantly impacts the American pharmaceutical industry.
As part of our services, we thoroughly reviewed our client’s citation count, publication record, and peer review experience. We learned that our client’s findings had been cited 424 times, that she had 23 publications to her name, and that she had conducted 50 peer-reviews at the time of filing. Additionally, she served on the editorial boards of 3 peer-reviewed pharmaceutical journals and had accepted an invitation to join the editorial board of yet another high impact journal. These impressive achievements were included in our client’s EB-1A petition packet and meticulously presented to the USCIS.
An important element of our client’s EB-1A petition was made up of the recommendation letters signed by other influential members of the scientific community. These letters were contributed by experts in the field of pharmaceutical sciences and they attested to the importance and significance of our client’s contributions. According to one of these letters: “She has a special combination of research skills that put her in a unique position with an excellent understanding of issues in drug optimization, drug resistance, and pharmacological issues.”
Because our client elected to file her case using Premium Processing (PP), she received notification of case approval just 8 days after filing. We congratulate her for securing a highly desirable EB-1A approval notice and we wish her the best as she continues to progress the field of pharmaceutical sciences in the US.